Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of the OxPhos Inhibitor ME-344 Combined With Bevacizumab in Previously Treated Metastatic Colorectal Cancer

NCT05824559 is registered in ClinicalTrials.gov with MEI Pharma, Inc. as lead sponsor.

NCT NCT05824559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05824559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of the OxPhos Inhibitor ME-344 Combined With Bevacizumab in Previously Treated Metastatic Colorectal Cancer
Lead sponsor
MEI Pharma, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
August 7, 2023
Completion date
July 23, 2024
Enrollment
23 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer